Supernus Pharmaceuticals (SUPN) potentially offers a rare combination of traditional value, backed by sales of its approved drugs, and upside excitement thanks to its high-potential pipeline ...

Supernus Pharmaceuticals has been profitable 8 times over the past 10 years. Its operating margin is 2.78% , which ranks worse than 57.94% of 1051 companies in the Drug Manufacturers industry.

Supernus Pharmaceuticals: Anti-CGRPs Are Causing Migraines For This Biotech But Investors Are Too Pessimistic Creating A Compelling Opportunity Aug. 14, 2019 3:46 PM ET Supernus Pharmaceuticals ...

Today, we revisit Supernus Pharmaceuticals, a fast-growing biopharma concern. We continue to hold this name despite stellar gains over the past two years due to its favorable long-term risk/reward ...

Supernus Pharmaceuticals sued Indian generic drugmaker Zydus Cadila and its U.S. subsidiary in Manhattan federal court on Friday for allegedly infringing 10 patents with its proposed generic of ...

The FDA has approved Supernus Pharmaceuticals' supplemental new drug application requesting a label expansion for Trokendi XR to include migraine headache prophylaxis in adults and adolescents ...

Supernus Pharmaceuticals (SUPN-0.03%) ... It's a good fit. It diversifies the company away from Trokendi which is approved for migraine and makes up a bulk of its sales.

Supernus Pharmaceuticals, Inc.SUPN announced that the FDA has granted a tentative approval to the company's supplemental New Drug Application (sNDA) for a label expansion for Trokendi XR to ...